Drug intelligence / Profile preview

anti-CD19 CAR-T cells with immunosuppressive receptor knockdown

Development stage: Unknown
Lead developer: The Sixth Affiliated Hospital of Sun Yat-Sen University
Modality: CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
Administration: Intravenous

Overview

Anti-CD19 CAR-T cells with immunosuppressive receptor knockdown is an autologous chimeric antigen receptor (CAR) T-cell therapy developed by The Sixth Affiliated Hospital of Sun Yat-sen University. The therapy consists of T cells engineered to express a CAR targeting the CD19 antigen, which is prevalent on B-cell malignancies. Additionally, these cells are modified using genetic knockdown techniques to reduce the expression of immunosuppressive receptors, aiming to enhance the persistence and anti-tumor efficacy of the CAR-T cells within the inhibitory tumor microenvironment. It is primarily being investigated in Phase 0/1 clinical trials for the treatment of relapsed or refractory B-cell malignancies, including diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma.

Other names: anti-CD19 CAR-T cells with immunosuppressive receptor knockdownanti-CD-19 CAR-T cells with immunosuppressive receptor knockdownanti-CD 19 CAR-T cells with immunosuppressive receptor knockdown

Targets

CD19 (B lymphocyte antigen CD19)

Beyond the preview

Go deeper on anti-CD19 CAR-T cells with immunosuppressive receptor knockdown.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on anti-CD19 CAR-T cells with immunosuppressive receptor knockdown.

Explore the full profile